HIV-1 TAR RNA: The target of molecular interactions between the virus and its host

被引:155
作者
Bannwarth, S
Gatignol, A [1 ]
机构
[1] McGill Univ, Lady Davis Inst Med Res, AIDS Ctr, Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Immunol & Med Microbiol, Montreal, PQ H3T 1E2, Canada
关键词
TAR RNA; Tat; acetylation; trans-activation; translation; TAR RNA binding proteins;
D O I
10.2174/1570162052772924
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV-1 TAR RNA is the binding site of the viral protein Tat, the trans-activator of the HIV-1 LTR. It is present at the 5' end of all HIV-1 spliced and unspliced mRNAs in the nucleus as well as in the cytoplasm. It has a highly folded stem-bulge-loop structure, which also binds cellular proteins to form ribonucleoprotein complexes. The Tat-Cyclin T1-CDK9 complex is the main component in the trans-activation of HIV-1 and its affinity for TAR is regulated through Tat acetylation by historic acetyl transferases. Recent studies show that this complex is able to recruit other cellular partners to mediate efficient transcriptional elongation. TRBP, PKR and La bind directly to the TAR RNA structure and influence translation of HIV-1 in either positive or negative manners. Some mutations in TAR RNA severely impair HIV-1 trans-activation, translation and viral production, showing its functional importance. The overexpression or suppression of several TAR RNA-binding proteins has a strong impact on viral replication pointing out their major role in the viral life cycle. TAR RNA has been the target of drug development to inhibit viral replication. Recent data using small molecules or RNA-based technologies show that acting on the TAR RNA or on its viral and cellular binding factors effectively decreases virion production.
引用
收藏
页码:61 / 71
页数:11
相关论文
共 187 条
[1]   RNA interference: Biology, mechanism, and applications [J].
Agrawal, N ;
Dasaradhi, PVN ;
Mohmmed, A ;
Malhotra, P ;
Bhatnagar, RK ;
Mukherjee, SK .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2003, 67 (04) :657-+
[2]  
Akkina R, 2003, ANTICANCER RES, V23, P1997
[3]   Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients [J].
Amado, RG ;
Mitsuyasu, RT ;
Rosenblatt, JD ;
Ngok, FK ;
Bakker, A ;
Cole, S ;
Chorn, N ;
Lin, LS ;
Bristol, G ;
Boyd, MP ;
Macpherson, JL ;
Fanning, GC ;
Todd, AV ;
Ely, JA ;
Zack, JA ;
Symonds, GP .
HUMAN GENE THERAPY, 2004, 15 (03) :251-262
[4]   Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity [J].
Ansari, SA ;
Safak, M ;
Gallia, GL ;
Sawaya, BE ;
Amini, S ;
Khalili, K .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :2629-2638
[5]   A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2′-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), α-L-LNA, or 2′-thio-LNA residues [J].
Arzumanov, A ;
Stetsenko, DA ;
Malakhov, AD ;
Reichelt, S ;
Sorensen, MD ;
Babu, BR ;
Wengel, J ;
Gait, MJ .
OLIGONUCLEOTIDES, 2003, 13 (06) :435-453
[6]   Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line [J].
Bannwarth, S ;
Talakoub, L ;
Letourneur, F ;
Duarte, M ;
Purcell, DF ;
Hiscott, J ;
Gatignol, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :48803-48813
[7]  
BANNWARTH S, UNPUB
[8]   NF-κB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II [J].
Barboric, M ;
Nissen, RM ;
Kanazawa, S ;
Jabrane-Ferrat, N ;
Peterlin, BM .
MOLECULAR CELL, 2001, 8 (02) :327-337
[9]   RNA interference - The short answer [J].
Bass, BL .
NATURE, 2001, 411 (6836) :428-429
[10]   Additive activity between the trans-activation response RNA-binding protein, TRBP2, and cyclin T1 on HIV type 1 expression and viral production in murine cells [J].
Battisti, PL ;
Daher, A ;
Bannwarth, S ;
Voortman, J ;
Peden, KWC ;
Hiscott, J ;
Mouland, AJ ;
Benarous, R ;
Gatignol, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2003, 19 (09) :767-778